Combining Measures of Immune Infiltration Shows Additive Effect on Survival Prediction in High-grade Serous Ovarian Carcinoma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2020 Apr 7

PMID 32249277

Citations 18

Authors

Anne Montfort

Rowan J Barker-Clarke

Anna M Piskorz

Anna Supernat

Luiza Moore

Sarwah Al-Khalidi

Steffen Bohm

Paul Pharoah

Jacqueline McDermott

Frances R Balkwill

James D Brenton

Affiliations

Soon will be listed here.

Abstract

Background: In colorectal and breast cancer, the density and localisation of immune infiltrates provides strong prognostic information. We asked whether similar automated quantitation and combined analysis of immune infiltrates could refine prognostic information in high-grade serous ovarian carcinoma (HGSOC) and tested associations between patterns of immune response and genomic driver alterations.

Methods: Epithelium and stroma were semi-automatically segmented and the infiltration of CD45RO, CD8 and CD68 cells was automatically quantified from images of 332 HGSOC patient tissue microarray cores.

Results: Epithelial CD8 [p = 0.027, hazard ratio (HR) = 0.83], stromal CD68 (p = 3 × 10, HR = 0.44) and stromal CD45RO (p = 7 × 10, HR = 0.76) were positively associated with survival and remained so when averaged across the tumour and stromal compartments. Using principal component analysis, we identified optimised multiparameter survival models combining information from all immune markers (p = 0.016, HR = 0.88). There was no significant association between PTEN expression, type of TP53 mutation or presence of BRCA1/BRCA2 mutations and immune infiltrate densities or principal components.

Conclusions: Combining measures of immune infiltration provided improved survival modelling and evidence for the multiple effects of different immune factors on survival. The presence of stromal CD68 and CD45RO populations was associated with survival, underscoring the benefits evaluating stromal immune populations may bring for prognostic immunoscores in HGSOC.

Citing Articles

YKL40/Integrin β4 Axis Induced by the Interaction between Cancer Cells and Tumor-Associated Macrophages Is Involved in the Progression of High-Grade Serous Ovarian Carcinoma.

Yamanaka K, Koma Y, Urakami S, Takahashi R, Nagamata S, Omori M Int J Mol Sci. 2024; 25(19).

PMID: 39408927 PMC: 11477481. DOI: 10.3390/ijms251910598.

PTEN Loss Shapes Macrophage Dynamics in High-Grade Serous Ovarian Carcinoma.

Spear S, Le Saux O, Mirza H, Iyer N, Tyson K, Grundland Freile F Cancer Res. 2024; 84(22):3772-3787.

PMID: 39186679 PMC: 7616669. DOI: 10.1158/0008-5472.CAN-23-3890.

Spatial tumor immune microenvironment phenotypes in ovarian cancer.

Mateiou C, Lokhande L, Diep L, Knulst M, Carlsson E, Ek S NPJ Precis Oncol. 2024; 8(1):148.

PMID: 39026018 PMC: 11258306. DOI: 10.1038/s41698-024-00640-8.

Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).

Aronson S, Walker C, Thijssen B, Van de Vijver K, Horlings H, Sanders J Br J Cancer. 2024; 131(3):565-576.

PMID: 38866963 PMC: 11300911. DOI: 10.1038/s41416-024-02731-6.

Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers.

Azzalini E, Stanta G, Canzonieri V, Bonin S Int J Mol Sci. 2023; 24(20).

PMID: 37894756 PMC: 10606847. DOI: 10.3390/ijms242015077.

References

Zhang L, Conejo-Garcia J, Katsaros D, Gimotty P, Massobrio M, Regnani G . Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003; 348(3):203-13. DOI: 10.1056/NEJMoa020177. View

Goode E, Block M, Kalli K, Vierkant R, Chen W, Fogarty Z . Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. 2017; 3(12):e173290. PMC: 5744673. DOI: 10.1001/jamaoncol.2017.3290. View

Zhang Z, Huang J, Zhang C, Yang H, Qiu H, Li J . Infiltration of dendritic cells and T lymphocytes predicts favorable outcome in epithelial ovarian cancer. Cancer Gene Ther. 2015; 22(4):198-206. DOI: 10.1038/cgt.2015.7. View

Milne K, Kobel M, Kalloger S, Barnes R, Gao D, Gilks C . Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One. 2009; 4(7):e6412. PMC: 2712762. DOI: 10.1371/journal.pone.0006412. View

Kroeger D, Milne K, Nelson B . Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer. Clin Cancer Res. 2016; 22(12):3005-15. DOI: 10.1158/1078-0432.CCR-15-2762. View

Leffers N, Gooden M, de Jong R, Hoogeboom B, ten Hoor K, Hollema H . Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother. 2008; 58(3):449-59. PMC: 11030692. DOI: 10.1007/s00262-008-0583-5. View

Fridman W, Zitvogel L, Sautes-Fridman C, Kroemer G . The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017; 14(12):717-734. DOI: 10.1038/nrclinonc.2017.101. View

Ali H, Dariush A, Thomas J, Provenzano E, Dunn J, Hiller L . Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial. Ann Oncol. 2017; 28(8):1832-1835. PMC: 5834010. DOI: 10.1093/annonc/mdx266. View

Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A . A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014; 7:19. PMC: 3939626. DOI: 10.1186/1757-2215-7-19. View

10.

Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View

11.

Pages F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G . In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009; 27(35):5944-51. DOI: 10.1200/JCO.2008.19.6147. View

12.

Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas H . Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell. 2017; 170(5):927-938.e20. PMC: 5589211. DOI: 10.1016/j.cell.2017.07.025. View

13.

Bowtell D, Bohm S, Ahmed A, Aspuria P, Bast Jr R, Beral V . Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015; 15(11):668-79. PMC: 4892184. DOI: 10.1038/nrc4019. View

14.

McAlpine J, Porter H, Kobel M, Nelson B, Prentice L, Kalloger S . BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. Mod Pathol. 2012; 25(5):740-50. DOI: 10.1038/modpathol.2011.211. View

15.

Zhou X, Hao Q, Lu H . Mutant p53 in cancer therapy-the barrier or the path. J Mol Cell Biol. 2018; 11(4):293-305. PMC: 6487791. DOI: 10.1093/jmcb/mjy072. View

16.

Kumar S, Mohan A, Guleria R . Prognostic implications of circulating anti-p53 antibodies in lung cancer--a review. Eur J Cancer Care (Engl). 2009; 18(3):248-54. DOI: 10.1111/j.1365-2354.2008.01019.x. View

17.

Peng W, Chen J, Liu C, Malu S, Creasy C, Tetzlaff M . Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2015; 6(2):202-16. PMC: 4744499. DOI: 10.1158/2159-8290.CD-15-0283. View

18.

Song H, Ramus S, Quaye L, Dicioccio R, Tyrer J, Lomas E . Common variants in mismatch repair genes and risk of invasive ovarian cancer. Carcinogenesis. 2006; 27(11):2235-42. DOI: 10.1093/carcin/bgl089. View

19.

Walters S, Maringe C, Butler J, Brierley J, Rachet B, Coleman M . Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership. Int J Cancer. 2012; 132(3):676-85. DOI: 10.1002/ijc.27651. View

20.

Martins F, de Santiago I, Trinh A, Xian J, Guo A, Sayal K . Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. Genome Biol. 2015; 15(12):526. PMC: 4268857. DOI: 10.1186/s13059-014-0526-8. View